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Background
Programme EVA Centre for AIDS Reagents (EVA CFAR) is
a reagent resource that provides well characterised
research materials and standards to the HIV/AIDS com-
munity. The reagent programme is one of the longest con-
tinually funded programmes in Europe and supports
projects based on the discovery and development of HIV/
AIDS vaccines and other prevention strategies. Although
considerable resources have been contributed by industry,
government and academia to this end, identification of an
efficacious HIV/AIDS vaccine has yet to be accomplished.
In this effort, EVA CFAR continues to support basic, pre-
clinical and clinical research for therapeutic and preventa-
tive strategies against HIV/AIDS.
Methods
Over the last two decades >4200 reagents have been
deposited, several acquired through project partnerships.
EVA CFAR actively participates in EC-supported projects
including (i) FP6 Specific Support Action (Neutnet); (ii)
FP6 AIDS Vaccine Integrated Project; (iii) FP6 European
Vaccines and Microbicides Enterprise (Network of Excel-
lence); (iv) FP7 project Next Generation HIV-1 Immuno-
gens that induce broadly reactive neutralizing antibodies.
The repository also collaborates with the Bill and Melinda
Gates-funded project that is part of the Collaboration for
AIDS Vaccine Discovery consortium.
Results
The repository has long provided researchers with special-
ised reagents, many which are commercially unavailable
and require customised production. The inventory availa-
ble at http://www.nibsc.ac.uk/spotlight/aids.html
includes cell lines, virus isolates, molecular clones, mon-
oclonal/polyclonal antibodies, peptides, recombinant
proteins and international standards and working rea-
gents for antibody and nucleic acid-based assays. The
enlargement of the repository is very much reliant on rea-
gents being donated from individual laboratories, how-
ever if a resource is needed in a specific research area
please contact Dr Meghna Ramaswamy Meghna.Ramas-
wamy@nibsc.hpa.org.uk or Mrs Sarah Goriup
Sarah.Goriup@nibsc.hpa.org.uk for information.
Conclusion
Programme EVA CFAR supports and facilitates the
exchange of reagents to new and promising areas of work
and encourages collaborative research and efforts aimed
at standardisation of reagents and methodologies.
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